Sarissa Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.7M | Hold |
9,188,635
| – | – | 21.75% | 2 |
|
|
2026
Q1 | $32.3M | Sell |
9,188,635
-6,730,800
| -42% | -$27.6M | 20.46% | 2 |
|
|
2025
Q4 | $53.6M | Hold |
15,919,435
| – | – | 24.07% | 2 |
|
|
2025
Q3 | $20.9M | Hold |
15,919,435
| – | – | 11.56% | 4 |
|
|
2025
Q2 | $11.4M | Sell |
15,919,435
-470,565
| -3% | -$369K | 7.4% | 5 |
|
|
2025
Q1 | $24.1M | Hold |
16,390,000
| – | – | 15.57% | 4 |
|
|
2024
Q4 | $72.6M | Hold |
16,390,000
| – | – | 22.49% | 2 |
|
|
2024
Q3 | $67.5M | Hold |
16,390,000
| – | – | 16.78% | 2 |
|
|
2024
Q2 | $107M | Hold |
16,390,000
| – | – | 18.04% | 3 |
|
|
2024
Q1 | $143M | Hold |
16,390,000
| – | – | 24.97% | 1 |
|
|
2023
Q4 | $188M | Hold |
16,390,000
| – | – | 28.9% | 1 |
|
|
2023
Q3 | $158M | Hold |
16,390,000
| – | – | 21.26% | 3 |
|
|
2023
Q2 | $174M | Hold |
16,390,000
| – | – | 17.36% | 3 |
|
|
2023
Q1 | $172M | Hold |
16,390,000
| – | – | 22.05% | 3 |
|
|
2022
Q4 | $203M | Hold |
16,390,000
| – | – | 24.17% | 2 |
|
|
2022
Q3 | $170M | Hold |
16,390,000
| – | – | 19.19% | 3 |
|
|
2022
Q2 | $189M | Hold |
16,390,000
| – | – | 19.02% | 2 |
|
|
2022
Q1 | $206M | Hold |
16,390,000
| – | – | 19.49% | 2 |
|
|
2021
Q4 | $191M | Hold |
16,390,000
| – | – | 16.54% | 3 |
|
|
2021
Q3 | $214M | Hold |
16,390,000
| – | – | 16.8% | 2 |
|
|
2021
Q2 | $211M | Hold |
16,390,000
| – | – | 16.77% | 3 |
|
|
2021
Q1 | $183M | Buy |
16,390,000
+2,350,000
| +17% | +$24.8M | 17.56% | 1 |
|
|
2020
Q4 | $160M | Hold |
14,040,000
| – | – | 16.32% | 1 |
|
|
2020
Q3 | $126M | Hold |
14,040,000
| – | – | 14.87% | 4 |
|
|
2020
Q2 | $145M | Buy |
14,040,000
+515,000
| +4% | +$5.27M | 16.12% | 3 |
|
|
2020
Q1 | $136M | Buy |
13,525,000
+3,218,000
| +31% | +$37.8M | 17.41% | 2 |
|
|
2019
Q4 | $137M | Buy |
10,307,000
+204,000
| +2% | +$2.25M | 11.39% | 3 |
|
|
2019
Q3 | $86.7M | Buy |
10,103,000
+385,000
| +4% | +$3.74M | 10.87% | 4 |
|
|
2019
Q2 | $106M | Buy |
9,718,000
+712,613
| +8% | +$7.98M | 13.25% | 4 |
|
|
2019
Q1 | $102M | Buy |
9,005,387
+1,540,141
| +21% | +$17.2M | 15.36% | 3 |
|
|
2018
Q4 | $64.8M | Buy |
7,465,246
+3,444,929
| +86% | +$39.5M | 14.35% | 4 |
|
|
2018
Q3 | $62.2M | Hold |
4,020,317
| – | – | 13.71% | 4 |
|
|
2018
Q2 | $64.4M | Hold |
4,020,317
| – | – | 12.91% | 3 |
|
|
2018
Q1 | $52M | Buy |
4,020,317
+2,050,217
| +104% | +$25.6M | 12.02% | 5 |
|
|
2017
Q4 | $24.7M | Buy |
+1,970,100
| New | +$25.7M | 6.33% | 6 |
|
Other funds holding IRWD
AC
Sarissa Capital Management's IRWD Position: Q2 2026 in Review
Sarissa Capital Management held its Ironwood Pharmaceuticals (IRWD) position steady in Q2 2026 at 9,188,635 shares worth $38.7M. The position accounts for 21.75% of the portfolio, ranked #2.
Sarissa Capital Management first reported a position in IRWD in Q4 2017 and has held it in 35 quarters since. The position peaked at $214M in Q3 2021. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.
- Sarissa Capital Management held 9,188,635 shares of Ironwood Pharmaceuticals worth $38.7M as of Q2 2026.
- Sarissa Capital Management left its Ironwood Pharmaceuticals share count unchanged in Q2 2026.
- Ironwood Pharmaceuticals made up 21.75% of Sarissa Capital Management's portfolio in Q2 2026, its #2 holding.
- Sarissa Capital Management first reported a position in Ironwood Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Sarissa Capital Management's Ironwood Pharmaceuticals position peaked at $214M in Q3 2021.
- 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.
Based on Sarissa Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.